Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC3 | Q13507 | 2/20 | 0.35 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 3/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | BCL9 | O00512 | 3/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988083 | 0.93 | TRPC3 (0.35) | TRPC3TRPC7JAK2JAK1MGLL | |
| SCHEMBL30393336 | 0.89 | TRPC3 (0.41) | TRPC3TRPC7JAK2JAK1MGLL | |
| SCHEMBL22987992 | 0.89 | TRPC3 (0.41) | TRPC3TRPC7JAK2JAK1MGLL | |
| SCHEMBL22987465 | 0.85 | TP53 (0.39) | TRPC3TRPC7NR1H2NR1H3USP30 | |
| SCHEMBL22987995 | 0.84 | BRD4 (0.38) | TRPC3TRPC7JAK2JAK1NR1H2 | |
| SCHEMBL22988318 | 0.84 | BRD4 (0.38) | TRPC3TRPC7JAK2JAK1NR1H2 | |
| SCHEMBL30393209 | 0.84 | BRD4 (0.38) | TRPC3TRPC7JAK2JAK1NR1H2 | |
| SCHEMBL30393124 | 0.84 | BRD4 (0.38) | TRPC3TRPC7JAK2JAK1NR1H2 | |
| SCHEMBL22987671 | 0.84 | TRPC3 (0.41) | TRPC3TRPC7JAK2JAK1NR1H2 | |
| SCHEMBL22988435 | 0.84 | JAK2 (0.30) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | TRPC3 905/4885TRPC7 953/4885JAK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.